Shangha'si I-Mab reported positive topline data from a Phase II trial of a selective IL-6 inhibitor in patients with ulcerative colitis. I-Mab says olamkicept is the only clinical stage IL-6 inhibitor that works via a trans-signaling mechanism. Other IL-6 therapies cause total inhibition of IL-6 signaling, including inhibiting homeostatic effects, which is associated with significant adverse events. In the double-blind Phase II trial, olamkicept met its primary and secondary endpoints. I-Mab acquired greater China rights to the IL-6 antagonist in 2016 from Swizterland's Ferring Pharma. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //